Literature DB >> 26034208

Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism.

Magdalena Rogalska-Taranta1, Antoaneta A Markova1, Andrzej Taranta1, Sebastian Lunemann1, Verena Schlaphoff1, Robert Flisiak1, Michael P Manns1, Markus Cornberg1, Anke R M Kraft1, Heiner Wedemeyer1.   

Abstract

Interferon α-mediated effector functions of NK cells may contribute to the control of HCV replication and the pathogenesis of liver disease. The single-nucleotide polymorphism rs12979860 near IFNL3 (previously known as IL28B) is important in response to IFN-α treatment and in spontaneous resolution of acute hepatitis C. The role of the IFNL3 polymorphism in NK cell function is unclear. Thus, we investigated the role of IFNL3 polymorphism in type I IFN-dependent regulation of NK cell functions in patients with cHC and healthy control subjects. We demonstrated a marked polarization of NK cells toward cytotoxicity in response to IFN-α stimulation in patients with hepatitis C. That TRAIL up-regulation was present, particularly in patients with the IFNL3-TT allele, was supported by a shift in the pSTAT-1:pSTAT-4 ratios toward pSTAT-1. In patients bearing the IFNL3-TT allele, NK cell effector function correlated with liver disease activity. In contrast, higher cytokine production of NK cells was observed in healthy individuals with the IFNL3-CC genotype, which may support spontaneous HCV clearance in acute infection. Overall, these findings show that the role of NK cells may differ in chronic infection vs. early antiviral defense and that the IFNL3 genotype differentially influences NK cell function. © Society for Leukocyte Biology.

Entities:  

Keywords:  HCV; IFN-α; IFN-γ; STATs; TRAIL; cytotoxicity

Mesh:

Substances:

Year:  2015        PMID: 26034208     DOI: 10.1189/jlb.4A1014-520R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.

Authors:  Elisavet Serti; Heiyoung Park; Meghan Keane; Ashley C O'Keefe; Elenita Rivera; T Jake Liang; Marc Ghany; Barbara Rehermann
Journal:  Gut       Date:  2016-01-04       Impact factor: 23.059

2.  Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C.

Authors:  Solomon Owusu Sekyere; Pothakamuri Venkata Suneetha; Svenja Hardtke; Christine Susanne Falk; Julia Hengst; Michael Peter Manns; Markus Cornberg; Heiner Wedemeyer; Verena Schlaphoff
Journal:  Front Immunol       Date:  2015-06-10       Impact factor: 7.561

3.  IL-28B Genetic Variants Determine the Extent of Monocyte-Induced Activation of NK Cells in Hepatitis C.

Authors:  Benjamin Krämer; Claudia Finnemann; Beatriz Sastre; Philipp Lutz; Andreas Glässner; Franziska Wolter; Felix Goeser; Pavlos Kokordelis; Dominik Kaczmarek; Hans-Dieter Nischalke; Christian P Strassburg; Ulrich Spengler; Jacob Nattermann
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

Review 4.  Type III Interferons in Hepatitis C Virus Infection.

Authors:  Maude Boisvert; Naglaa H Shoukry
Journal:  Front Immunol       Date:  2016-12-23       Impact factor: 7.561

5.  Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.

Authors:  Cody Orr; Wenjie Xu; Henry Masur; Shyam Kottilil; Eric G Meissner
Journal:  BMC Infect Dis       Date:  2020-12-04       Impact factor: 3.090

6.  IFN-λ3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infection.

Authors:  Marion Depla; Sandy Pelletier; Nathalie Bédard; Camille Brunaud; Julie Bruneau; Naglaa H Shoukry
Journal:  Immun Inflamm Dis       Date:  2016-08-16

7.  Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C.

Authors:  Anna Wróblewska; Agnieszka Bernat; Anna Woziwodzka; Joanna Markiewicz; Tomasz Romanowski; Krzysztof P Bielawski; Tomasz Smiatacz; Katarzyna Sikorska
Journal:  Clin Exp Med       Date:  2016-04-28       Impact factor: 3.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.